Two Phase I designs are implemented in the package: the classical 3+3 and the Continual Reassessment Method. Simulations tools are also available to estimate the operating characteristics of the methods with several user-dependent options.

Author | Benjamin Esterni with contribution from Baboukar Mane |

Date of publication | 2015-02-20 10:31:31 |

Maintainer | Christophe Zemmour <zemmourc@ipc.unicancer.fr> |

License | GPL (>= 2) |

Version | 1.0.1 |

**aip:** Functions to calculate the appropriate dose level singletons

**CreData:** Creates a CRM dataframe

**Crm:** Dose-escalation with the Continual Reassessment Method

**fp:** Density functions

**Lp:** Likelihood functions

**psip:** Dose-Toxicity modelisation functions

**sim3p3:** Simulation of one dose-escalation study with the classical...

**simCrm:** Simulation of one dose-escalation study with the Continual...

**ssim3p3:** Simulation of n dose-escalation study with the 3+3 design

**ssimCrm:** Simulation of n dose-escalation study with the Continual...

**troisPtrois:** Dose escalation with the 3+3 design

**UBCRM-package:** UBCRM is a package containing functions to simulate and...

**updata:** Update the CRM dataframe after new patients' collected data

UBCRM

UBCRM/inst

UBCRM/inst/NEWS

UBCRM/NAMESPACE

UBCRM/R

UBCRM/R/Lp.R
UBCRM/R/psip.R
UBCRM/R/aip.R
UBCRM/R/ssim3p3.R
UBCRM/R/sim3p3.R
UBCRM/R/ait1.R
UBCRM/R/ait2.R
UBCRM/R/update.R
UBCRM/R/ail2.R
UBCRM/R/simCrm.R
UBCRM/R/CreData.R
UBCRM/R/troisPtrois.R
UBCRM/R/psit.R
UBCRM/R/ail1.R
UBCRM/R/fl.R
UBCRM/R/Ll.R
UBCRM/R/Crm.R
UBCRM/R/ssimCrm.R
UBCRM/R/psil.R
UBCRM/R/ft.R
UBCRM/R/Lt.R
UBCRM/R/fp.R
UBCRM/MD5

UBCRM/DESCRIPTION

UBCRM/man

UBCRM/man/troisPtrois.Rd
UBCRM/man/Crm.Rd
UBCRM/man/aip.Rd
UBCRM/man/ssim3p3.Rd
UBCRM/man/ssimCrm.Rd
UBCRM/man/psip.Rd
UBCRM/man/updata.Rd
UBCRM/man/Lp.Rd
UBCRM/man/UBCRM-package.Rd
UBCRM/man/simCrm.Rd
UBCRM/man/fp.Rd
UBCRM/man/sim3p3.Rd
UBCRM/man/CreData.Rd
Questions? Problems? Suggestions? Tweet to @rdrrHQ or email at ian@mutexlabs.com.

All documentation is copyright its authors; we didn't write any of that.